ATXS (Astria Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ATXS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-23 | Christopher Morabito | Chief Medical Officer | D | — | — |
| 2026-01-23 | Andrew Komjathy | Chief Commercial Officer | D | — | — |
| 2026-01-23 | Andrea Matthews | Chief Business Officer | D | — | — |
| 2026-01-23 | Noah Clauser | Chief Financial Officer | D | — | — |
| 2026-01-23 | Benjamin Harshbarger | Chief Legal Officer | D | — | — |
| 2026-01-23 | Fred Callori | Director | D | — | — |
| 2026-01-23 | Jonathan Violin | Director | D | — | — |
| 2026-01-23 | ANTHONY GREGG LAPOINTE | Director | D | — | — |
| 2026-01-23 | MICHAEL D KISHBAUCH | Director | D | — | — |
| 2026-01-23 | SUNIL AGARWAL | Director | D | — | — |
| 2026-01-23 | KENNETH BATE | Director | D | — | — |
| 2026-01-23 | Hugh M Cole | Director | D | — | — |
| 2026-01-23 | Jill C. Milne | CEO and President | D | — | — |
| 2026-01-23 | Joanne T. Beck | Director | D | — | — |
| 2025-06-12 | MICHAEL D KISHBAUCH | Director | A | — | — |
| 2025-06-12 | ANTHONY GREGG LAPOINTE | Director | A | — | — |
| 2025-06-12 | KENNETH BATE | Director | A | — | — |
| 2025-06-12 | Joanne T. Beck | Director | A | — | — |
| 2025-06-12 | SUNIL AGARWAL | Director | A | — | — |
| 2025-06-12 | Jonathan Violin | Director | A | — | — |
| 2025-06-12 | Fred Callori | Director | A | — | — |
| 2025-06-12 | Hugh M Cole | Director | A | — | — |
| 2025-03-25 | Andrea Matthews | Chief Business Officer | A | — | — |
| 2025-03-25 | Andrew Komjathy | Chief Commercial Officer | A | — | — |
| 2025-03-25 | Jill C. Milne | CEO and President | A | — | — |
| 2025-03-25 | Christopher Morabito | Chief Medical Officer | A | — | — |
| 2025-03-25 | Noah Clauser | Chief Financial Officer | A | — | — |
| 2025-03-25 | Benjamin Harshbarger | Chief Legal Officer | A | — | — |
| 2024-06-06 | Jonathan Violin | Director | A | — | — |
| 2024-06-06 | Hugh M Cole | Director | A | — | — |
| 2024-06-06 | Fred Callori | Director | A | — | — |
| 2024-06-06 | Joanne T. Beck | Director | A | — | — |
| 2024-06-06 | KENNETH BATE | Director | A | — | — |
| 2024-06-06 | ANTHONY GREGG LAPOINTE | Director | A | — | — |
| 2024-06-06 | MICHAEL D KISHBAUCH | Director | A | — | — |
| 2024-04-09 | SUNIL AGARWAL | Director | A | — | — |
| 2024-04-03 | Christopher Morabito | Chief Medical Officer | MIXED | — | — |
| 2024-02-12 | Noah Clauser | Chief Financial Officer | A | — | — |
| 2024-02-12 | Andrea Matthews | Chief Business Officer | A | — | — |
| 2024-02-12 | Andrew Komjathy | Chief Commercial Officer | A | — | — |
| 2024-02-12 | Christopher Morabito | Chief Medical Officer | A | — | — |
| 2024-02-12 | Jill C. Milne | CEO and President | A | — | — |
| 2024-02-12 | Benjamin Harshbarger | Chief Legal Officer | A | — | — |
| 2024-02-05 | Perceptive Xontogeny Venture Fund, LP | Director | Buy | — | — |
| 2024-01-30 | Christopher Morabito | Chief Medical Officer | MIXED | — | — |
| 2023-12-22 | Perceptive Xontogeny Venture Fund, LP | Director | Buy | — | — |
| 2023-10-18 | JOSEPH EDELMAN | Director | Buy | — | — |
| 2023-06-06 | Andrew Komjathy | Chief Commercial Officer | A | — | — |
| 2023-06-06 | Jonathan Violin | Director | A | — | — |
| 2023-06-06 | ANTHONY GREGG LAPOINTE | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,873,721 | — |
| — | Director | 1,652,371 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATXS quote page; the site-wide leaderboard is on the insider transactions hub.